Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone781-457-9000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$105.56 million
Profitability
Miscellaneous
Employees133
Next Earnings Date10/23/2019 (Estimated)
OptionableOptionable
Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions
What is Anika Therapeutics' stock symbol?
Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."
How were Anika Therapeutics' earnings last quarter?
Anika Therapeutics Inc (NASDAQ:ANIK) announced its quarterly earnings data on Wednesday, July, 24th. The biotechnology company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.42 by $0.25. The biotechnology company earned $30.42 million during the quarter, compared to analyst estimates of $27.41 million. Anika Therapeutics had a return on equity of 11.27% and a net margin of 26.87%. Anika Therapeutics's quarterly revenue was down .4% compared to the same quarter last year. During the same period last year, the company earned $0.68 earnings per share. View Anika Therapeutics' Earnings History.
When is Anika Therapeutics' next earnings date?
What guidance has Anika Therapeutics issued on next quarter's earnings?
Anika Therapeutics issued an update on its FY 2019 earnings guidance on Wednesday, July, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $106.61055-109.7772 million, compared to the consensus revenue estimate of $101.89 million.
What price target have analysts set for ANIK?
4 brokerages have issued 1-year price targets for Anika Therapeutics' stock. Their predictions range from $35.00 to $54.00. On average, they anticipate Anika Therapeutics' share price to reach $46.00 in the next twelve months. This suggests that the stock has a possible downside of 15.2%. View Analyst Price Targets for Anika Therapeutics.
What is the consensus analysts' recommendation for Anika Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 hold rating, 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Anika Therapeutics.
What are Wall Street analysts saying about Anika Therapeutics stock?
Here are some recent quotes from research analysts about Anika Therapeutics stock:
- 1. According to Zacks Investment Research, "Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. " (7/26/2019)
- 2. Barrington Research analysts commented, "We are maintaining our OUTPERFORM investment rating on ANIK shares and are increasing our price target to $49 (from $45 previously). We arrive at our price target by attaching a 15x multiple to our 2020 adjusted EBITDA estimate. We assume $140 million in net cash 12 months from now." (7/25/2019)
Has Anika Therapeutics been receiving favorable news coverage?
News articles about ANIK stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Anika Therapeutics earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Anika Therapeutics.
Are investors shorting Anika Therapeutics?
Anika Therapeutics saw a decrease in short interest in August. As of August 31st, there was short interest totalling 2,694,400 shares, a decrease of 18.1% from the July 31st total of 3,288,000 shares. Based on an average daily volume of 191,600 shares, the short-interest ratio is currently 14.1 days. Approximately 20.1% of the shares of the company are short sold. View Anika Therapeutics' Current Options Chain.
Who are some of Anika Therapeutics' key competitors?
Some companies that are related to Anika Therapeutics include Nevro (NVRO), Glaukos (GKOS), Irhythm Technologies (IRTC), Cardiovascular Systems (CSII), Merit Medical Systems (MMSI), Atrion (ATRI), Silk Road Medical (SILK), Cryolife (CRY), Luminex (LMNX), Orthofix Medical (OFIX), Tactile Systems Technology (TCMD), AtriCure (ATRC), Shockwave Medical (SWAV), Axonics Modulation Technologies (AXNX) and Cerus (CERS).
What other stocks do shareholders of Anika Therapeutics own?
Who are Anika Therapeutics' key executives?
Anika Therapeutics' management team includes the folowing people:
- Mr. Joseph G. Darling, CEO, Pres & Director (Age 61)
- Ms. Sylvia Cheung, CFO, Treasurer & Sec. (Age 44)
- Dr. Edward S. Ahn, Chief Technology & Strategy Officer (Age 47)
- Mr. Thomas M. Finnerty, Chief HR Officer (Age 61)
- Mr. Alexei Goraltchouk, VP of Operations
Who are Anika Therapeutics' major shareholders?
Anika Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.67%), Kayne Anderson Rudnick Investment Management LLC (11.81%), Vanguard Group Inc. (6.65%), Renaissance Technologies LLC (3.22%), D. E. Shaw & Co. Inc. (3.00%) and BTIM Corp. (2.61%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Glenn R Larsen, Jeffery S Thompson, Joseph G Darling, Joseph L Bower, Raymond J Land and Richard Hague. View Institutional Ownership Trends for Anika Therapeutics.
Which major investors are selling Anika Therapeutics stock?
ANIK stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Capital Management Corp VA, Invesco Ltd., Marshall Wace LLP, Pinebridge Investments L.P., South Dakota Investment Council, JPMorgan Chase & Co. and Bank of America Corp DE. Company insiders that have sold Anika Therapeutics company stock in the last year include Glenn R Larsen, Jeffery S Thompson, Joseph L Bower and Raymond J Land. View Insider Buying and Selling for Anika Therapeutics.
Which major investors are buying Anika Therapeutics stock?
ANIK stock was purchased by a variety of institutional investors in the last quarter, including Jefferies Group LLC, BTIM Corp., D. E. Shaw & Co. Inc., Natixis Advisors L.P., Renaissance Technologies LLC, Morgan Stanley, 361 Capital LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Anika Therapeutics.
How do I buy shares of Anika Therapeutics?
Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Anika Therapeutics' stock price today?
One share of ANIK stock can currently be purchased for approximately $54.27.
How big of a company is Anika Therapeutics?
Anika Therapeutics has a market capitalization of $748.00 million and generates $105.56 million in revenue each year. The biotechnology company earns $18.72 million in net income (profit) each year or $1.84 on an earnings per share basis. Anika Therapeutics employs 133 workers across the globe.View Additional Information About Anika Therapeutics.
What is Anika Therapeutics' official website?
How can I contact Anika Therapeutics?
Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]
MarketBeat Community Rating for Anika Therapeutics (NASDAQ ANIK)
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe ANIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days.
